Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

Blue Cross Blue Shield of Massachusetts announced that it expanded its care options for members with diabetes.

For 2025, Insulet expects revenue growth between 16% and 20%. It projects Omnipod sales to increase by 17%-21%.

A study highlighted the accuracy of three leading continuous glucose monitors (CGM), including systems from Abbott and Dexcom.